Author: Ravi Shankar

• Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors
• Started first backfill cohorts in the ongoing Phase 1b NECTINIUM-2 clinical trial of AKY-1189 and Phase 1b BActinium-1 clinical trial of AKY-2519
• On track to present preliminary data for AKY-1189 in first quarter of 2027 and AKY-2519 in 2027

BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including progress with the Company’s two clinical-stage programs.

“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision,” said Matthew Roden, Ph.D., President and Chief Executive Officer at Aktis Oncology. “With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies. This substantial clinical progress is a testament to our ability to execute rapidly with quality across multiple clinical trials and positions Aktis for a data-rich 2027.”

Third quarter 2026 and recent business highlights

AKY-1189

AKY-1189 is a novel, clinical-stage miniprotein radioconjugate designed to selectively deliver actinium-225 (²²⁵Ac) to tumors expressing Nectin-4, a clinically and commercially validated target expressed in several tumor types, including locally advanced or metastatic urothelial cancer (mUC) and breast cancer.

• Dose escalation is ongoing in the Phase 1b NECTINIUM-2 trial evaluating AKY-1189 in patients with locally advanced or mUC and other Nectin-4 expressing solid tumors.
• Aktis initiated backfill at the 6 MBq dose level to further characterize safety and preliminary antitumor activity in up to 30 patients. This is the first of up to two dose levels planned to be selected for backfill.

AKY-2519

AKY-2519 is a novel, clinical-stage miniprotein radioconjugate designed to selectively deliver ²²⁵Ac to tumors expressing B7-H3, a clinically validated target expressed in prostate, lung, and other solid tumors.

• Aktis initiated the Phase 1b BActinium-2 trial evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing solid tumors.
• Dose escalation is ongoing in the Phase 1b BActinium-1 trial evaluating AKY-2519 in patients with metastatic castration-resistant prostate cancer (mCRPC), including PLUVICTO®-naïve and PLUVICTO-experienced patients.
• In the Phase 1b BActinium-1 trial, Aktis initiated backfill at the 9 MBq dose level for both the PLUVICTO-naïve and PLUVICTO-experienced cohorts to further characterize safety and preliminary antitumor activity in up to 30 patients per cohort. This is the first of up to two planned dose levels that will be backfilled in each of the mCRPC patient populations.

Dr. Roden added, “With our robust end-to-end supply chain supported by multiple contract manufacturing organizations and isotope suppliers, we are successfully delivering clinical supply for our clinical trials nationally. In the quarter, we operationalized our in-house GMP facility at 17 Drydock in Boston, where we expect to begin supplying drug product for our clinical trials in the first half of 2027, further expanding manufacturing capacity for clinical supply. The 17 Drydock facility progresses our strategy to build capabilities to support potential Phase 3 trials and commercial product supply in a capital-efficient manner.”

Manufacturing

• Aktis began manufacturing drug product in its in-house GMP facility, as part of the Company’s hybrid sourcing manufacturing strategy. Aktis intends to amend the INDs for AKY-2519 and AKY-1189 to include the in-house facility as a manufacturer of clinical supply for its ongoing clinical trials.

Anticipated milestones for the next 12 months

• AKY-1189: Expect preliminary data from the ongoing Phase 1b NECTINIUM-2 trial in the first quarter of 2027.
• AKY-2519: Expect preliminary data from the ongoing Phase 1b BActinium-1 trial in 2027.
• Early pipeline: Two programs tracking toward development candidate nomination and commencement of IND-enabling activities in the first quarter of 2027.
• Corporate: Expect to expand drug supply to include our in-house GMP facility to support ongoing clinical trials in the first half of 2027.

Third quarter 2026 financial results

• Cash position: Cash, cash equivalents, and marketable securities were $492.9 million as of September 30, 2026, compared with $226.8 million as of December 31, 2025. The increase in cash, cash equivalents, and marketable securities reflects net proceeds from the Company’s initial public offering in January 2026, primarily offset by cash used in operations. The Company’s cash, cash equivalents, and marketable securities as of September 30, 2026, are expected to fund the Company’s operating plan into 2029.
• Collaboration revenue: Collaboration revenue was $3.9 million for the quarter ended September 30, 2026, compared with $1.6 million for the comparable prior-year period. The increase of $2.3 million was attributable to continued advancement of the Company’s research collaboration with Eli Lilly and Company, with revenue recognized over time using the cost incurred input method.
• R&D expenses: Research and development expenses were $32.1 million for the quarter ended September 30, 2026, compared with $16.5 million for the comparable prior-year period. The increase of $15.6 million was primarily driven by the advancement of clinical trials for AKY-1189 and AKY-2519 and increased headcount primarily in clinical development and manufacturing to support the advancement of the clinical pipeline.
• G&A expenses: General and administrative expenses were $6.5 million for the quarter ended September 30, 2026, compared with $3.3 million for the comparable prior-year period. The increase of $3.2 million was primarily due to increased headcount to support company growth and increased activities associated with operating as a public company.
• Net loss: Net loss was $29.9 million for the quarter ended September 30, 2026, compared with $15.5 million for the comparable prior-year period. The increase of $14.4 million was primarily driven by higher operating expenses, partially offset by increased collaboration revenue recognized and interest income, net.

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is a registered trademark of Novartis Pharmaceuticals Corporation.

About NECTINIUM-2
The Phase 1b multicenter, open-label clinical trial is evaluating AKY-1189 in patients with locally advanced or mUC, breast cancer and other Nectin-4 expressing tumors. The trial will explore up to 5 dose levels in the dose escalation. Per protocol, Aktis has the ability to expand enrollment in backfill cohorts at selected dose levels and tumor types to generate additional clinical data while dose escalation continues. The trial is being conducted in the U.S. Additional information about the trial is available at clinicaltrials.gov using the identifier NCT07020117.

About BActinium-1
The Phase 1b multicenter, open-label clinical trial is evaluating AKY-2519 in patients with mCRPC, including PLUVICTO-naïve and PLUVICTO-experienced cohorts. The study will explore up to 3 dose levels in the dose escalation. Per protocol, Aktis has the ability to expand enrollment in backfill cohorts at selected dose levels to generate additional clinical data while dose escalation continues. The trial is being conducted in the U.S. Additional information about the trial is available at clinicaltrials.gov using the identifier NCT07581184.

About BActinium-2
The Phase 1b multicenter, open-label trial is evaluating AKY-2519 in patients with NSCLC and other B7-H3 expressing solid tumors. The study will explore up to 3 dose levels in the dose escalation. Per protocol, Aktis has the ability to expand enrollment at selected dose levels and tumor types to generate additional clinical data while dose escalation continues. The trial is being conducted in the U.S. Additional information about the trial is available at clinicaltrials.gov using the identifier NCT07887971.

About Aktis’ miniprotein radioconjugate platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, and other solid tumor cancers. Aktis’ second clinical-stage pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis’ miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit www.aktisoncology.com.

Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company’s expectations about the timing and results of ongoing and planned clinical trials and regulatory filings, goals to develop and commercialize its product candidates, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to the commencement and completion of the Company’s ongoing and planned clinical trials, the Company’s limited operating history, its ability to generate positive clinical trial results for its product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which the Company is subject, competitive pressures, risks relating to business interruptions, and other risks set forth under the heading “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequent filings with the Securities and Exchange Commission. The Company’s actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update or revise these forward-looking statements.

AKTIS ONCOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In thousands)
(Unaudited)
		Three Months Ended September 30,						Nine Months Ended September 30,
		2026			2025			2026			2025
Revenue:
Collaboration revenue	$	3,905		$	1,579		$	10,516		$	4,627
Operating expenses:
Research and development		32,125			16,467			77,441			50,958
General and administrative		6,527			3,315			19,427			10,978
Total operating expenses		38,652			19,782			96,868			61,936
Loss from operations		(34,747)			(18,203)			(86,352)			(57,309)
Other income (expense):
Interest income		4,822			2,682			13,971			8,761
Other expense, net		(14)			(12)			(27)			(45)
Total other income, net		4,808			2,670			13,944			8,716
Net loss	$	(29,939)		$	(15,533)		$	(72,408)		$	(48,593)

AKTIS ONCOLOGY, INC. BALANCE SHEET DATA (In thousands) (Unaudited)
	September 30,	December 31,
	2026	2025
Cash, cash equivalents, and marketable securities	$             492,929	$             226,787
Total assets	532,484	264,885
Total liabilities	73,612	77,625
Total stockholders’ equity and redeemable convertible preferred stock	$             458,872	$             187,260

Media contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com

Investor contact:
Precision AQ
Alex Lobo
212-698-8802
Alex.lobo@precisionaq.com

Efficient form factor delivers advanced space domain awareness directly to the warfighter in the field

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in defense, national security, and global markets, today announced the release of KnownSpace^® Recon+™, a portable satellite terminal that escapes the limitations of traditional Space Domain Awareness (SDA) by integrating multiple Radio Frequency (RF) SDA capabilities into a single deployable unit.

Recon+ is a commercially available product. Units have already been purchased by multiple U.S. government agencies.

KnownSpace Recon+ introduces a new approach to SDA in the field by enabling operators to assess the RF environment from any location, detect and classify satellite signals, characterize activity and support advanced SDA missions with one portable system. The collection of capabilities was previously limited to enterprise grade systems at fixed gateway locations. Its design allows rapid deployment from a single device that can be integrated through cloud or gateway systems.

Historically, SDA has been defined by optical systems and radar, both of which have severe limitations on their ability to collect useful information. The advent of modern RF signal monitoring tools from companies like Kratos has dramatically expanded the depth, breadth and availability of that data about friendly and unfriendly satellite activity and their users on the ground. With Recon+, Kratos now frees warfighters from another historical limitation, putting these capabilities in a portable unit that can be carried into the field.

For example, with Recon+ individual warfighters or teams in multiple remote locations can monitor certain types of activity that reveal which satellites are transmitting and receiving in the vicinity, obtain insights into their activity, behavior, interference and changes over time. Recon+ also provides insights into local signal behaviors conducted on the ground, such as interference or jamming sources.

Recon+ can be configured in a variety of form factors to meet a range of mission-specific goals, ranging from fly-away kits to transportable units that can be deployed at command posts or mounted on a vehicle. Built on Kratos OpenSpace® architecture, multiple Recon+ units can be networked for remote operations, extending RF awareness across dispersed locations while enabling connectivity and data sharing with other SDA systems. Its software-defined architecture also supports cloud connectivity and third-party software integration, allowing capabilities to be added and adapted as mission needs evolve. Together, these features underscore that Recon+ can be quickly tailored for mission-specific objectives while remaining highly portable.

“As the latest addition to the KnownSpace solutions family,” said Hugh White, vice president of SDA & Space Superiority at Kratos, “Recon+ helps defense and other government agencies escape the limits of traditional ground systems with a powerful, flexible way for users to understand the RF activity in space and respond in real time.”

About KnownSpace
Kratos KnownSpace RF signal-based Space Domain Awareness (SDA) solutions are reinventing our understanding of space as a warfighting domain by providing deeper insights about allied, adversary and commercial operations across orbital and ground environments and the links in between. Extending beyond the limitations of traditional radar and optical technologies, KnownSpace RF SDA capabilities include enterprise applications, gateway-based products and tactical solutions such as KnownSpace Recon+ a portable, cloud-enabled SDA terminal. Kratos also delivers real-time SDA services through its global KnownSpace Network of more than 190 sensors and 20 locations, the largest commercially owned, commercially operated (COCO) RF sensor network. Services include signal survey and characterization, tracking and maneuver, interference mitigation, geolocation, and more. For more information visit www.KratosSpace.com/KnownSpace.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Kratos Investor Information:
877-934-4687
investor@kratosdefense.com

Naples, Italy and Hamilton, Bermuda, Nov. 12, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), is a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games and growing its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”). Savoia is investing in the next generation through three complementary models: a youth program, a network of affiliated football schools, and a new Academy planned for the 2027/28 season. Each serves young players and their families in a different way, and each adds its own value to the Club.

The Youth Program

Savoia selects promising players aged 6 to 17 based on merit and potential, and covers the cost of their participation. Alongside technical coaching, the program teaches responsibility and respect for the rules, so families know their children are growing as people as well as players. For the Club, it builds a pipeline of talent and lasting sporting value. Many soccer clubs generate substantial revenue by transferring their pipeline of talent to other teams.

Affiliated Football Schools

Through affiliation, Savoia shares its coaching approach with local football schools, beginning with Scuola Calcio Azzurri, which works with more than 300 children. The Club covers fees for families who cannot afford them, giving children a safe place to play and a team to belong to, including those growing up in families affected by Camorra organized crime or the imprisonment of a parent. Savoia hopes to extend the network across Italy, widening its social impact and bringing the Savoia name and goodwill to more communities.

The Academy

For the 2027/28 season, the Club plans to complete the process to secure the concession for Stadio Alfredo Giraud and run the academy directly as a fee-paying school. It is aimed at families who want their children to enjoy the game and train with experienced professionals in a structured, college-inspired setting, and it will reflect the Club’s ties to the Royal House of Savoy, whose coat of arms appears on its shirts. For the Club, it adds a new line of business supported by enrollment fees.

Scuola Calcio Azzurri celebrates the end of the youth season, recognizing the dedication and achievements of its young players, coaches and families.

Opening the Game to Every Family

“Savoia is doing good in the community, fostering goodwill, and building our brand while we invest in the next generation of footballers to develop the talent that we believe will foster continued excellence and profitability in the future.”

General Manager and Chief Operating Officer of Savoia, Nazario Matachione.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company’s three mobile games in development include Regalia Cards (card game), Palazzo Chronicles (match-3 castle and garden-building game) and Viva Verdi (trading card game). The Company is also actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

• Scuola Calcio Azzurri celebrates the end of the youth season, recognizing the dedication and achievements of its young players, coaches and families

Continued Progress Across Pipeline Supports Expanded Therapeutic Opportunities

SOLANA BEACH, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, obesity, dermatologic, ophthalmic, and neurological conditions, today provided a business update and announced its financial and operational results for the third quarter ended September 30, 2026.

Business Highlights

ART27.13:

• Expanding Development Opportunities in Obesity: New nonclinical findings demonstrated approximately 20% weight loss with ART27.13 monotherapy, comparable to semaglutide, and approximately 40% weight loss when combined with semaglutide in a diet-induced obesity animal model. The combination also further improved oral glucose tolerance and increased bone mineral density, effects not observed in any other treatment group. The results support ART27.13’s potential as a treatment for obesity, both independently and in combination with GLP-1 therapies, expanding beyond cancer supportive care towards a total weight management solution.
• Strengthening Intellectual Property and Clinical Potential: Artelo filed a provisional patent application covering ART27.13 for obesity and combination use with GLP-1 receptor agonists. Artelo also received Notices of Allowance in the U.S. and Japan for patent claims covering the intended commercial formulation of ART27.13.  The U.S. patent, once issued, is expected to extend protection through 2041. The Company continues to pursue multiple indications, supported by previously reported Phase 2 CAReS interim findings demonstrating improvements in body weight, lean body mass and physical activity in patients experiencing cancer-related anorexia and weight loss.
• Second Phase 2 Study Initiated in Glaucoma: Enrollment is already underway for the investigator-led DREAM trial, a Phase 2 study evaluating whether oral daily treatment with ART27.13 can lower intraocular pressure in people with glaucoma or ocular hypertension.

ART26.12:

• Advancing First-in-Human FABP5 Inhibitor for Non-Opioid Pain Treatment: Plans for ART26.12, the first selective fatty acid binding protein 5 (FABP5) inhibitor evaluated in humans, anticipate a Phase 1 multiple ascending dose (MAD) study to initiate in the fourth quarter of 2026. Previously reported single ascending dose results demonstrated favorable safety and tolerability, predictable pharmacokinetics and exposure levels supporting further clinical development.
• Strengthening Scientific Evidence and Industry Engagement: Artelo presented ART26.12 data at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain and at BIO-Europe 2026, highlighting its differentiated mechanism of action and potential to address significant unmet needs in chronic pain. Reported nonclinical findings indicate ART26.12’s potential across multiple pain indications, including chemotherapy-induced peripheral neuropathy, spinal cord injury and osteoarthritis, where it achieved pain relief levels comparable to naproxen with significantly less gastric tissue damage.

“We are gratified that our programs are moving closer to key clinical milestones and revealing new development opportunities,” said Gregory D. Gorgas, President and Chief Executive Officer. “Our immediate priority is advancing ART26.12 into its next stage of clinical testing, where we aim to amplify the encouraging results observed to date. At the same time, the expanding potential of ART27.13 is generating opportunities with potential strategic partners in significant new therapeutic markets.”

Q3 2026 Financial Results

• R&D Expenses: Research and development expenses were $0.8 million for the quarter ended September 30, 2026, compared to $1.3 million for the quarter ended September 30, 2025.
• G&A Expenses: General and administrative expenses were $1.0 million for the quarter ended September 30, 2026, compared to $1.8 million in the quarter ended September 30, 2025.
• Net Loss: For the quarter ended September 30, 2026, net loss was $1.8 million, or $3.19 per basic and diluted common share, compared to a net loss of $3.1 million for the quarter ended September 30, 2025.
• Cash and Investments: Cash totaled $4.4 million as of September 30, 2026.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in obesity, anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth or partnering opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that results observed in nonclinical animal models may not be predictive of, or replicated in, human clinical trials; the uncertainty of patent protection and the potential for intellectual property challenges; the highly competitive nature of the pharmaceutical industry, including the market for pain therapeutics; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; the timing, content and availability of the Company’s presentation at the IASP 2026 World Congress on Pain; and our ability to enter into partnering or licensing arrangements on acceptable terms, or at all. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com

Latest $1 million order brings cumulative orders to nearly $6 million since program started, with potential additional opportunities expected in 2027 and 2028

Follow-on production orders reflect continued customer demand for next-generation GNSS testing and simulation platform

ESCONDIDO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today announced that a leading defense and intelligence contractor has placed a new $1 million follow-on production order in support of a next-generation GNSS testing and simulation platform. This is the 10^th order from this customer since the relationship began in May 2025 and follows a $1 million production order announced on October 8, 2026. The aggregate value of orders received under the program since May 2025 now totals approximately $6 million. OSS believes the program may present additional order opportunities in 2027 and 2028.

“This latest order reflects the continued production activity associated with our customer’s next-generation platform,” said Mike Knowles, President and CEO of OSS. “Since establishing this relationship in May 2025, we have received ten orders totaling nearly $6 million, with the pace of orders accelerating as the program transitions from development into production. This is exactly the type of multi-year opportunity we are working to build across our defense and commercial markets, where initial platform wins can develop into sustained production programs.”

Under the latest order, OSS will provide its Gen 5 PCIe 4U short-depth server (SDS) as the compute foundation for the customer’s next-generation GNSS simulation platform, to support expected demand in 2027. The platform is a multi-element, phase-coherent GNSS simulator designed specifically for Controlled Reception Pattern Antenna (CRPA) testing and can simultaneously simulate multiple threats, including jamming, spoofing and repeating.

About One Stop Systems
One Stop Systems, Inc. (Nasdaq: OSS) is a leader in AI enabled solutions for the demanding ‘edge’. OSS designs and manufactures Enterprise Class compute and storage products that enable rugged AI, sensor fusion and autonomous capabilities without compromise. These hardware and software platforms bring the latest data center performance to harsh and challenging applications, whether they are on land, sea or in the air.

OSS products include ruggedized servers, compute accelerators, flash storage arrays, and storage acceleration software. These specialized compact products are used across multiple industries and applications, including autonomous trucking and farming, as well as aircraft, drones, ships and vehicles within the defense industry.

OSS solutions address the overall AI workflow, from high-speed data acquisition to deep learning, training and large-scale inference, and have delivered many industry firsts for industrial OEM and government customers.

As one of the fastest growing segments of the multi-billion-dollar edge computing market, AI enabled solutions require-and OSS delivers-the highest level of performance in the most challenging environments without compromise.

OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com. You can also follow OSS on X, YouTube, and LinkedIn.

Forward-Looking Statements
One Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Statements in this press release include, but are not limited to, statements regarding the performance and capabilities of OSS’ products, including their ability to satisfy applicable customer, technical and performance requirements; the expected timing, scope and continuation of the customer’s program; potential future orders and opportunities relating to the program, including in 2027 and 2028; the timing and amount of revenue expected to be recognized from existing orders and any potential future orders; the future adoption of OSS’ technologies and applications by this or other customers; and the development and expansion of the Company’s multi-year platform opportunities, offerings and customer relationships in the defense and commercial markets. These statements are based on the Company’s current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our latest Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Contacts:
Paul “PK” Averna
One Stop Systems, Inc.
Tel (703) 509-5631
Email contact

Investor Relations:
Andrew Berger
Managing Director
SM Berger & Company, Inc.
Tel (216) 464-6400
Email contact

Strong NPM-139 safety and tolerability profile:

-0 of 10 NPM-139 subjects experienced adverse events reported as treatment related
-5 of 10 Wegovy subjects (control group) experienced adverse events reported as treatment related (gastrointestinal only, consistent with marketed GLP-1 therapies)

Encouraging NPM-139 semaglutide release profile:

-No NPM-139 rapid drug exposure increases; maximum drug levels from a single administration measured at ~16 days (versus ~2.4 days for the Wegovy control group)
-NPM-139 semaglutide delivery was encouraging and consistent with preclinical performance
-Comparable weight loss was observed between the NPM-139 and Wegovy groups

Clinical advancement supported:

-Vivani will advance NPM-139 towards a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027
-Vivani will explore the potential for clinical development of NPM-139 in GLP-1-naïve patients based on the positive SLIM-1 tolerability profile

ALAMEDA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants utilizing its proprietary NanoPortal™ technology, today reported positive top-line results from SLIM-1, the Company’s recently completed Phase 1 trial of low-dose NPM-139 (semaglutide implant) and a control group of low-dose Wegovy™ (semaglutide injection). NPM-139 is a subdermal implant being designed for once or twice-yearly administration under development for chronic weight management in obese or overweight patients.

“The positive top-line data from our SLIM-1 Phase 1 trial marks a critical milestone for Vivani, demonstrating encouraging clinical translation from preclinical models to humans, an encouraging delivery profile, and a strong tolerability profile,” said Adam Mendelsohn, CEO of Vivani Medical. “Real-world data show a staggering level of GLP-1 therapy dropoff. By some estimates, more than 50% of GLP-1 users discontinue their therapy within a single year, with gastrointestinal side effects driving much of this attrition. The long-term health outcomes and related pharmacoeconomic value that have been associated with GLP-1 therapy are only realized when patients remain on treatment for durations significantly longer than one year. The absence of rapid drug exposure increases from the NPM-139 group is both desirable and reassuring because rapid increases in drug concentrations have been associated with tolerability issues with other GLP-1 therapies. The strong NPM-139 safety and tolerability profile in SLIM-1 reinforces our belief that NPM-139 may directly address a major reason for attrition in GLP-1 therapies, while simultaneously improving medication adherence and convenience for patients.”

Dr. Mendelsohn continued, “We don’t know of any other company that is developing miniature, ultra-long-acting, GLP-1 implants that make possible a once- or twice-yearly administration frequency, with the reversibility speed of a weekly injection. We expect that quick reversibility will be a compelling feature for certain segments of the GLP-1 market who would like an ultra-long-acting option but would need one that offers quick reversibility, including the approximately 23% of GLP-1 users who are women of child-bearing age due to recommendations against continued GLP-1 use during pregnancy.”

Vivani Chairman of the Board, Gregg Williams, stated, “I’m very excited about the new top-line SLIM-1 data released today and continue to believe these miniature, ultra-long-acting drug implants have the potential to revolutionize the treatment of chronic diseases including obesity and type 2 diabetes. I remain committed to supporting the development of Vivani’s portfolio of innovative drug implants and the ultimate benefits these new therapeutic options may deliver to prescribers and their patients.”

About SLIM-1™

SLIM-1 is an open-label, active-controlled clinical trial evaluating a low-dose NPM-139 (semaglutide implant) given to 10 participants, and the starting dose of Wegovy (0.25mg/week semaglutide injection) given to a control group of 10 participants, over a four-week duration. The trial was designed to evaluate the safety, tolerability and pharmacokinetic profile in overweight or obese participants who are otherwise healthy. Changes in weight were also measured.

SLIM-1 was conducted in a single study center in Australia. Implant insertions and removals were brief and successfully completed without any complications. The Wegovy group experienced weight loss of 0.82 percent and the NPM-139 group experienced weight loss of 0.79 percent. No serious adverse events (AEs) were reported in the study.

Vivani continues to support Novo Nordisk’s evaluation of NPM-139 and the NanoPortal technology under the non-exclusive agreement announced in July 2026.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the safety, tolerability, therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on November 12, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:

Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462

Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462

Award recognizes TTEC Digital’s rapid growth and enterprise momentum across the NiCE ecosystem

AUSTIN, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — TTEC Digital, one of the largest pure-play customer experience (CX) solutions partners for data, AI, and security, today announced that TTEC Digital has earned NiCE Rising Star of the Year in the NiCE Channel Partner Awards. The award recognizes a partner that built early momentum through fresh capabilities, commitment, and customer-focused execution.

“Being recognized as Rising Star of the Year underscores the momentum TTEC Digital has built as a strategic partner for enterprises transforming customer experience through agentic AI and the NiCE platform,” said Brad Scott, vice president of TTEC Digital’s NiCE practice. “Our focus extends beyond technology implementation as we help clients reimagine the end-to-end customer journey, accelerate time to value, and translate innovation into measurable business outcomes at scale. The depth of our technical expertise and cross-platform integration within the NiCE and Cognigy ecosystem, combined with the speed at which we continue to expand our capabilities and deliver value for our clients, is what differentiates TTEC Digital in the market.”

The award follows a sustained record of robust delivery and a strong pipeline aligned to NiCE solutions, particularly CXone, NiCE’s purpose-built, AI-powered customer experience platform, which leverages natively-integrated Cognigy capabilities to deploy advanced agentic and conversational AI.

“Big ideas move faster when the right partners put them into action, and this year’s NiCE Channel Partner Award winners are transforming ambition into momentum,” said Dorothy Copeland, chief partner officer, NiCE. “TTEC Digital earned Rising Star of the Year by opening new markets, accelerating enterprise growth, and helping customers turn complex transformation into measurable progress. Their achievements reflect what becomes possible when deep expertise, bold thinking, and powerful technology come together.”

The partnership between TTEC Digital and NiCE is designed to help clients realize high-impact outcomes, including:

• Enterprise platform savings: Measurable annual cost savings through platform consolidation and modernization.
• CX transformation return: Increased project ROI through comprehensive, AI-powered customer experience transformation.
• AI self-service efficiency: Measurable reductions in associate-assisted interactions via generative AI solutions.

The Rising Star of the Year award builds on TTEC Digital’s recent recognition as a NiCE Platinum Partner and its selection as a launch partner for the NiCE AI Specialization Program — together underscoring TTEC Digital’s leadership, technical expertise, and commitment to advancing AI-powered customer experience innovation.

For more information about TTEC Digital and NiCE, visit https://www.ttecdigital.com/partners/nice.

About NiCE
NiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE’s platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes.

About TTEC Digital

TTEC Digital is one of the largest pure-play customer experience (CX) technology partners globally, with a deep foundation in data, AI, and security with 2,000 technologists that innovate, architect, integrate, and operate CX technology solutions for more than 1,000 clients across North America, Europe and Asia Pacific. TTEC Digital defines CX as everything that happens between a company and its customers: every conversation, every channel, every touchpoint, and the technology that makes those experiences possible. Certified at the highest tier across every major CX technology platform covering data, analytics, contact center, CRM, cloud, and frontier AI, we are a single accountable partner, from the first architecture decision through deployment and ongoing operations. The company’s professional services, managed services, proprietary software, and forward-deployed engineers give clients the depth of a global firm and the agility of a strategic partner — measured on outcomes delivered, not hours billed. Learn more at ttecdigital.com.

CONTACT: Media Contact

Meredith Matthews

meredith.matthews@ttec.com

As international demand grows, EagleNXT expands post-delivery training and user evaluation to get operators mission-ready faster 

ALLEN, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (d/b/a EagleNXT) (NYSE American: UAVS), a leading provider of full-stack drone, sensor, counter-UAS, and software solutions, today announced drone sales into seven countries in a single week, spanning North America, Latin America, Europe, and Africa, and serving the commercial, public safety, and defense markets with several additional orders in process. As its international customer base grows, EagleNXT is expanding post-delivery training and support and increasing its focus on user testing and evaluation, so customers get more from their systems and reach field-use faster.

“Selling into seven countries in a single week tells us customers trust our platforms. What maintains that trust is what happens after delivery,” said Bill Irby, CEO of EagleNXT. “Our operators work in very different environments, and their feedback goes straight into how we test and develop new technology. We believe that approach helps us deliver proven capabilities sooner and deepen customer relationships that support long-term shareholder value.”

After-Delivery Training and Support

EagleNXT’s customer commitment extends beyond delivery through hands-on training, responsive technical support, and dedicated customer service. The Company’s focus is on helping operators use their systems effectively and maintain mission readiness throughout the customer relationship. Its Technical Support team in Lausanne, Switzerland, supports this commitment to customers worldwide.

Renewed Focus on User Testing and Evaluation

EagleNXT is renewing its focus on conducting user testing and evaluation of new technology to accelerate its introduction. By bringing direct operator feedback into the development process, the Company aims to identify practical requirements earlier, refine new capabilities around real-world use, and shorten the path from evaluation to introduction. This effort is intended to make user experience a more direct driver of product development.

For more information about the full suite of EagleNXT products and UAS solutions, contact the EagleNXT Sales team.

About EagleNXT

EagleNXT is a leading provider of full-stack drones, advanced sensors, counter-UAS, and intelligent software solutions that deliver critical aerial intelligence for defense, government, and commercial applications worldwide. With more than one million flights conducted globally, EagleNXT’s platforms are trusted across defense, public safety, agriculture, infrastructure, and environmental monitoring applications. The Company’s drone systems have achieved multiple industry firsts, including FAA approvals for Operations Over People (OOP) and Beyond Visual Line of Sight (BVLOS), as well as EASA C2 certification in Europe and inclusion on the U.S. Department of Defense’s Blue UAS list. EagleNXT’s sensors are integrated on more than 150 different drone models and are used in over 100 research publications worldwide, reinforcing its leadership in precision agriculture, surveying, and environmental sustainability initiatives. For more information, visit https://eaglenxt.com or follow EagleNXT on LinkedIn.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on EagleNXT’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the Company’s ability to recruit, integrate and retain qualified sales personnel; the effectiveness of the Company’s sales and channel partner strategies; the timing and fulfillment of current and future purchase orders; the conversion of customer opportunities into revenue; demand for the Company’s products in the agriculture, public safety and defense markets; the availability and timing of government and defense funding; risks associated with international operations; and competition in the unmanned systems market. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, see the risk disclosures in the Company’s most recently filed Annual Report on Form 10-K and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC. All such forward-looking statements speak only as of the date they are made, and EagleNXT undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

Media Contact
Erica Diverio
ericad@seeztoday.com
+1 (908) 229-0724

Investor Relations Contact
Email: UAVS@EagleNXT.com

Good Housekeeping’s 2027 Home Reno Awards recognize Sunrun Flex™ battery-plus-solar subscription for protecting households when their energy needs increase, while also providing backup power and hedging against rising energy costs

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, announced today that its Sunrun Flex™ home energy subscription was named a winner in Good Housekeeping’s 2027 Home Reno Awards. Flex is the first solar and battery storage solution designed to adapt to customers’ changing energy needs. The full list of awards can be found here.

“Our judges like how Sunrun continues to innovate its pricing models,” said Dan DiClerico, the Good Housekeeping Institute’s Home Improvement & Outdoor Lab Director. “With Sunrun Flex, homeowners can now lease a system that will meet their expanding power needs. That’s important, as we know that most households add more electric components, such as heat pumps, electric vehicles, and induction cooktops, to their homes after going solar.”

This is the second time Sunrun has been recognized in Good Housekeeping’s Home Reno Awards. In 2025, Good Housekeeping’s Home Reno Awards recognized Sunrun’s battery-plus-solar home energy subscription service as a Sustainability Innovator.

“From a practical and financial standpoint, Sunrun Flex maximizes value and adaptability. We designed Flex to give customers peace of mind that they will have enough energy to manage life’s inevitable changes,” said Sunrun President and Chief Revenue Officer Paul Dickson. “By removing the guesswork from energy production and storage, we ensure our customers stay protected even when consumption increases due to home improvements, a growing family, or extreme weather.”

Traditional home solar systems are sized for a household’s current energy usage—leaving families under-resourced as future needs increase. Flex systems are sized above a customer’s pre-solar usage to ensure extra energy is always available, whether a customer adds an EV, new appliances, or other home improvements.

Sunrun Flex customers enjoy a predictable monthly minimum payment while only paying for extra energy above their baseline when they use it at a locked-in Flex Rate. Flex also delivers the full benefits of Sunrun’s home battery storage offering, including automatic backup power during outages, protection against utility rate hikes, and support for the community’s power grid. Learn more about Sunrun Flex here.

Each year, engineers and product analysts at the Good Housekeeping Institute, together with a team of home improvement professionals, spend months rigorously evaluating the best products and services for home remodeling and maintenance. As part of the evaluation process, analysts send products into the homes of consumer testers to see how they perform in real-world conditions, while GH design pros weigh in on style and aesthetics. To determine the winners, judges focus on key attributes including quality, value, efficiency, sustainability, and overall design appeal.

About Sunrun

Sunrun Inc. (Nasdaq: RUN) is America’s largest provider of home battery storage, solar, and home-to-grid power plants. As the pioneer of home energy systems offered through a no-upfront-cost subscription model, Sunrun empowers customers nationwide with greater energy control, security, and independence. Sunrun supports the grid by providing on-demand dispatchable power that helps prevent blackouts and lowers energy costs. Learn more at www.sunrun.com.

Media Contact
Wyatt Semanek
Sr. Director, Corporate Communications
press@sunrun.com

Investor & Analyst Contact
Patrick Jobin
SVP, Deputy CFO & Investor Relations Officer
investors@sunrun.com

PHILADELPHIA and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Cohen & Company Inc. (NYSE American: COHN) (“Cohen & Company” or the “Company”) today announced that Daniel G. Cohen, Executive Chairman of the Board, has been appointed Chief Executive Officer, effective as of November 10, 2026. Mr. Cohen succeeds Lester R. Brafman, who stepped down from his role as Chief Executive Officer effective as of the close of business on November 10, 2026. Mr. Brafman will remain with the Company as a Senior Advisor through November 30, 2026, to support an orderly transition. Daniel Cohen will continue to serve as Executive Chairman of the Board.

Daniel Cohen previously served as Chief Executive Officer and Chief Investment Officer of the Company from December 2009 to September 2013. Having also served on the Board since 1999 and as Executive Chairman since May 2022, Mr. Cohen has deep experience and unparalleled insight across the Company’s businesses and strategic priorities. As Chief Executive Officer, Mr. Cohen will focus on the Company’s business strategy, operations, and corporate vision.

“I know firsthand the strength of our team and our platform, and I look forward to building on our strong foundation as we execute on our priorities and create long-term value for our stockholders,” said Daniel Cohen. “I am excited to return to the CEO role and continue working with our team to capitalize on the opportunities ahead and drive results through disciplined execution and a clear commitment to profitable growth.”

Mr. Cohen continued, “On behalf of the Board, I want to thank Lester for his leadership and the significant contributions he has made to Cohen & Company over the past thirteen plus years. We wish him all the best.”

Mr. Brafman added, “It has been a privilege to lead Cohen & Company, and I am proud of all we have accomplished together. I look forward to seeing the Company’s continued success.”

Third Quarter 2026 Financial Results

In a separate press release issued today, Cohen & Company announced its financial results for the third quarter of 2026. Daniel Cohen will join Joseph Pooler, Executive Vice President, Chief Financial Officer and Treasurer to discuss the quarterly results on the Company’s investor conference call today at 10:00 a.m. Eastern Time.

The conference call will be available via webcast. Interested parties can access the webcast by clicking the webcast link on the Company’s homepage at www.cohenandcompany.com.

About Cohen & Company

Cohen & Company is a financial services company specializing in an expanding range of capital markets and asset management services. Cohen & Company’s operating segments are Capital Markets, Asset Management, and Principal Investing. The Capital Markets segment consists of sales, trading, gestation repo financing, new issue placements in corporate and securitized products, underwriting, and advisory services, operating primarily through Cohen & Company’s subsidiaries, Cohen & Company Securities, LLC (“Cohen Securities”) in the United States and Cohen & Company Financial (Europe) S.A. in Europe. A division of Cohen Securities, Cohen & Company Capital Markets (“CCM”) is the Company’s full-service boutique investment bank providing capital markets and SPAC advisory services to corporations, financial sponsors, investors, and institutions. The Capital Markets business segment also includes investment returns on financial instruments that the Company has received as consideration for investment banking and new issue services provided by CCM. The Asset Management segment manages and services assets through investment funds, managed accounts, joint ventures, and collateralized debt obligations. As of September 30, 2026, the Company had approximately $1.3 billion of assets under management in primarily fixed income assets in a variety of asset classes including European bank and insurance trust preferred securities, debt issued by small and medium sized European, U.S., and Bermudian insurance and reinsurance companies, and servicing commercial real estate loans. The Principal Investing segment is comprised primarily of investments the Company has made for the purpose of earning an investment return rather than investments made to support its trading or other capital markets business activity. For more information, please visit www.cohenandcompany.com.

Forward-looking Statements

This communication contains certain statements, estimates, and forecasts with respect to future performance and events. These statements, estimates, and forecasts are “forward-looking statements.” In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seek,” or “continue” or the negatives thereof or variations thereon or similar terminology. All statements other than statements of historical fact included in this communication are forward-looking statements and are based on various underlying assumptions and expectations and are subject to known and unknown risks, uncertainties, and assumptions, and may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially from the results, level of activity, performance, or achievements expressed or implied in the forward-looking statements including, but not limited to, those discussed under the heading “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition” in our filings with the Securities and Exchange Commission (“SEC”), which are available at the SEC’s website at www.sec.gov and our website at www.cohenandcompany.com/investor-relations/sec-filings. Such risk factors include the following: (a) a decline in general economic conditions or the global financial markets, including those caused by inflation, rising interest rates, and the current geopolitical situation, (b) unfavorable market conditions may lead to a reduction in revenues from our investment banking and new issue revenues, including from underwriting and placement activities, (c) losses caused by financial or other problems experienced by third parties, (d) losses due to unidentified or unanticipated risks, (e) a lack of liquidity, i.e., ready access to funds for use in our businesses, (f) the ability to attract and retain personnel, (g) litigation and regulatory proceedings, (h) reputational harm due to losses or our inability to sell securities we purchase as an underwriter at the anticipated price levels, (i) competitive pressure, (j) an inability to generate incremental income from new or expanded businesses, (k) unanticipated market closures or effects due to inclement weather or other disasters, (l) losses (whether realized or unrealized) on our principal investments, (m) the possibility that payments to the Company of subordinated management fees from its CDOs will continue to be deferred or will be discontinued, (n) the possibility that the Company’s stockholder rights plan may fail to preserve the value of the Company’s deferred tax assets, whether as a result of the acquisition by a person of 5% of the Company’s common stock or otherwise, (o) the Company’s reduction in the volume of its investments into SPACs, (p) the difficulty in identifying potential business combinations as a result of increased competition in the SPAC market, (q) the value of the Company’s holdings of founders shares in post-business combination companies is volatile and may decline and the possibility that significant portions of the founder shares may remain restricted for a long period of time, (r) the possibility that the Company will stop paying quarterly dividends to its stockholders, and (s) that CCM’s gross pipeline of possible transactions may not result in transactions that are consummated and total recognition of all pipeline fees. As a result, there can be no assurance that the forward-looking statements included in this communication will prove to be accurate or correct. In light of these risks, uncertainties, and assumptions, the future performance or events described in the forward-looking statements in this communication might not occur. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results and we do not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Investors –	Media –
Cohen & Company Inc.	Joele Frank, Wilkinson Brimmer Katcher
Joseph W. Pooler, Jr.	Joseph Sala or Zach Genirs
Executive Vice President and Chief Financial Officer	212-355-4449
215-701-8952
investorrelations@cohenandcompany.com